BridgeBio Pharma is having a banner week, with the Bay Area company’s encaleret acing a phase 3 trial just days after another ...
BBP-418 hit the mark in the phase 3 FORTIFY trial by achieving a significant increase in glycosylated alpha-dystroglycan (αDG ...
BridgeBio Pharma has caught Wall Street’s attention after the company shared positive Phase 3 results from its FORTIFY trial for BBP-418 in limb-girdle muscular dystrophy type 2I/R9. The treatment ...
BridgeBio Pharma’s analyst price target has ticked up, with the consensus fair value estimate rising from $66.32 to $66.47 per share. This modest upward revision reflects increased optimism about the ...
Already sky high after the success of its limb-girdle muscular dystrophy therapy, reported on Monday, BridgeBio’s shares rose nearly 8% more as encaleret balanced calcium levels in patients with a ...
By Padmanabhan Ananthan (Reuters) -BridgeBio Pharma's experimental drug for a rare genetic condition that causes low blood calcium met all the main and secondary goals in a late-stage study, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback